The Leading Cause of Death Worldwide
Despite current standard of care treatments, residual risk of MI, stroke and death remains high in patients with CVD. Developing new treatments is a challenge due to the heterogeneity of the patient population and the resulting variation in response to treatment.
Scientific advances in precision medicine now allow for a patient’s genetic profile to be considered during the development of new treatments. This targeted approach identifies individual patients who may benefit from a particular treatment, based on a specific genetic subtype.
DalCor is developing dalcetrapib, the first precision medicine aiming to reduce fatal and non-fatal MI above and beyond the current standard of care in patients who carry the ADCY9 rs1967309 AA genotype.